Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cephalon, a US-based biopharmaceutical company, has announced that Nuvigil (armodafinil) tablets, a longer-lasting formulation of modafinil, is now available. Nuvigil is indicated to improve wakefulness throughout the day for patients who struggle with excessive sleepiness, mainly associated with treated obstructive sleep apnea, shift work sleep disorder, and narcolepsy.
Subscribe to our email newsletter
Frank Baldino, Chairman and CEO, Cephalon, said:” We are proud to be able to bring Nuvigil to physicians and patients and to increase access to the medication through our patient support programs. Physicians have told us that they want and need a longer-lasting medication for their patients, and Nuvigil delivers on that need,
Cephalon provides treatments for central nervous system disorders, pain and cancer. The company’s research pipeline is focused on developing new compounds and new indications for existing products, while its business collaborations capitalize on new products and smart drug delivery systems.